gankyrin Inhibitors
Gankyrin inhibitors are a group of compounds that can reduce the function of gankyrin, either directly or indirectly, through their actions on various biochemical and cellular pathways. Gankyrin, an oncoprotein, is involved in several key cellular processes including cell cycle progression, cell proliferation, and apoptosis. Consequently, it influences numerous signaling pathways such as the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, SRC/FAK pathway, and EGFR/RAS/RAF/MEK/ERK pathway among others. The inhibitors of gankyrin range from kinase inhibitors, mTOR inhibitors to cyclin-dependent kinase inhibitors, each with a specific target and mode of action that ultimately results in the modulation of gankyrin's activity. Kinase inhibitors, such as sorafenib, dasatinib, gefitinib, selumetinib, trametinib, lapatinib, sunitinib, nilotinib, and vemurafenib, function by inhibiting specific kinases involved in the various signaling pathways that gankyrin supports. For instance, sorafenib, a RAF kinase inhibitor, can attenuate the RAF/MEK/ERK pathway, leading to a decrease in gankyrin's enhancing effect on cell proliferation and survival. Similarly, dasatinib, a BCR-ABL and SRC family kinase inhibitor, can disrupt the SRC/FAK pathway, reducing gankyrin's effect on cell migration and invasion.
mTOR inhibitors, such as everolimus and rapamycin, function by inhibiting mTOR, a key component of the PI3K/AKT/mTOR pathway. By disrupting this pathway, these inhibitors can reduce gankyrin's promoting effect on cell proliferation and survival. Palbociclib, on the other hand, is a selective inhibitor of cyclin-dependent kinases 4 and 6. Its action on these kinases disrupts the cell cycle, a process that gankyrin is known to promote, leading to a decrease in gankyrin's impact on cell proliferation. In summary, gankyrin inhibitors are a diverse group of compounds that can modulate the activity of gankyrin by influencing various biochemical and cellular pathways that gankyrin supports. These inhibitors offer a potential means of controlling gankyrin's role in cell proliferation, survival, and migration.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple kinases including RAF kinases, VEGFR, and PDGFR. In the context of gankyrin, it can attenuate the RAF/MEK/ERK pathway, which gankyrin is known to support. This can lead to a decrease in gankyrin's enhancing effect on cell proliferation and survival. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor. By inhibiting mTOR, it can disrupt the PI3K/AKT/mTOR pathway, which gankyrin is known to promote. As a result, everolimus can lead to a decrease in gankyrin's impact on cell proliferation and survival. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and SRC family kinases. By inhibiting these kinases, it can disrupt pathways that gankyrin is known to enhance, including the SRC/FAK pathway, leading to a decrease in gankyrin's effect on cell migration and invasion. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor. By inhibiting EGFR, it can disrupt the EGFR/RAS/RAF/MEK/ERK pathway, which gankyrin is known to support, leading to a decrease in gankyrin's effect on cell proliferation and survival. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor. By disrupting the RAS/RAF/MEK/ERK pathway, which gankyrin is known to support, selumetinib can reduce gankyrin's enhancing effect on cell proliferation and survival. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that targets the RAS/RAF/MEK/ERK pathway. By inhibiting this pathway, trametinib can reduce gankyrin's enhancing effect on cell proliferation and survival. | ||||||
Lapatinib ditosylate | 388082-78-8 | sc-202205B sc-202205 sc-202205A | 5 mg 10 mg 25 mg | $49.00 $77.00 $117.00 | 15 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2/neu. By inhibiting these receptors, it can disrupt pathways that gankyrin is known to enhance, reducing gankyrin's effect on cell proliferation and survival. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that targets PDGFR and VEGFR, among others. By inhibiting these receptors, it can disrupt pathways that gankyrin is known to enhance, reducing gankyrin's effect on cell proliferation and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it can disrupt the PI3K/AKT/mTOR pathway, which gankyrin is known to promote. As a result, rapamycin can lead to a decrease in gankyrin's impact on cell proliferation and survival. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a tyrosine kinase inhibitor that targets BCR-ABL. By inhibiting BCR-ABL, it can disrupt pathways that gankyrin is known to enhance, leading to a decrease in gankyrin's effect on cell proliferation and survival. | ||||||